SONN — Sonnet Biotherapeutics Holdings Cashflow Statement
0.000.00%
- $2.92m
- -$0.87m
- $0.15m
- 20
- 18
- 42
- 16
Annual cashflow statement for Sonnet Biotherapeutics Holdings, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -18.5 | -24.3 | -25 | -29.7 | -18.8 |
Depreciation | |||||
Non-Cash Items | 12.7 | 7.25 | 1.33 | 1.93 | 0.594 |
Discontinued Operations | |||||
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.074 | 1.4 | 1.09 | 0.093 | -3.12 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -4.05 | -15.6 | -22.6 | -27.7 | -21.3 |
Capital Expenditures | -0.473 | -0.076 | -0.004 | -0.896 | -0.443 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1.15 | — | — | — | — |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.679 | -0.076 | -0.004 | -0.896 | -0.443 |
Financing Cash Flow Items | 3.19 | -5.98 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 3.34 | 23 | 42.8 | 4.01 | 21 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.023 | 7.31 | 20.3 | -24.6 | -0.779 |